Who is sponsoring NCT04353518?

NCT04353518 is sponsored by Cadila Pharnmaceuticals.

What drugs are being tested in NCT04353518?

Interventions in NCT04353518: Suspension of heat killed (autoclaved) Mycobacterium w, Placebo.

Is NCT04353518 still recruiting?

NCT04353518 is currently status unknown. Last updated 22 December 2020.

Last reviewed 2020-12-22 · How we verify

NCT04353518

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Trial to Evaluate Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19

Status unknown Phase 3 Last updated 22 December 2020

What this trial tests

Phase 3 trial testing Suspension of heat killed (autoclaved) Mycobacterium w in COVID-19 in 4,000 participants. Status unknown.

Timeline

30 June 2020

Primary endpoint
30 March 2021

30 May 2021

Quick facts

Lead sponsor	Cadila Pharnmaceuticals
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	4,000
Start date	30 June 2020
Primary completion	30 March 2021
Estimated completion	30 May 2021
Sites	3 locations across India

Drugs / interventions tested

Suspension of heat killed (autoclaved) Mycobacterium w — full drug profile →
Placebo

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

Cadila Pharnmaceuticals — full company profile →

Who can join

18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This clinical trial is a randomized, blinded, two arms, placebo controlled, clinical trial to evaluate the safety and efficacy of Mycobacterium w in combination with standard care as per hospital practice to prevent COVID 19 in subjects at risk of getting infected with COVID 19.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Primed for global coronavirus pandemic: Emerging research and clinical outcome.
Ahamad S, Branch S, Harrelson S, Hussain MK, et al · · 2021 · cited 25× · PMID 33070079 · DOI 10.1016/j.ejmech.2020.112862
Will bacille Calmette-Guerin immunization arrest the COVID-19 pandemic?
Ehtesham NZ, Samal J, Ahmad F, Arish M, et al · · 2020 · cited 7× · PMID 32859863 · DOI 10.4103/ijmr.ijmr_1563_20
Clinical trial protocols of repurposed prophylaxis for COVID-19: A review.
Sallard E, Belhadi D, Lescure FX, Yazdanpanah Y, et al · · 2021 · cited 3× · PMID 33022293 · DOI 10.1016/j.medmal.2020.09.013
Repurposed prophylaxis strategies for COVID-19: a review
Sallard E, Lescure F, Burdet C, Guedj J, et al · · 2020 · DOI 10.1101/2020.05.30.20117937

Verify or expand the search:

Other trials of Suspension of heat killed (autoclaved) Mycobacterium w

Trials testing the same drug.

NCT04358809 — Clinical Trial of Mycobacterium w in COVID-19 Positive Patients, Hospitalized But Not Critically Ill · Phase 3 · unknown
NCT04347174 — A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients · NA · completed

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Cadila Pharnmaceuticals trials

Trials by the same sponsor.

NCT04358809 — Clinical Trial of Mycobacterium w in COVID-19 Positive Patients, Hospitalized But Not Critically Ill · Phase 3 · unknown
NCT04347174 — A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients · NA · completed
NCT04801199 — Effect of CPL-2009-0031 in the Treatment of Patients With Uncontrolled Type 2 Diabetes Mellitus · Phase 3 · completed
NCT05174598 — A Clinical Trial to Evaluate Efficacy and Safety of Two Different Formulations of Topical Calcipotriol in Patients With · Phase 3 · completed
NCT00694915 — Study of Mycobacterium w in Superficial Transitional Cell Carcinoma of Bladder · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04353518 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cadila Pharnmaceuticals
Last refreshed: 22 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04353518.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing